Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 190-199

  Pai, Manjunath P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Glycylcyclines; Minocycline; Obesity; Pharmacodynamics; Pharmacology

Indexed keywords

TIGECYCLINE;

ACINETOBACTER BAUMANNII; ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TOLERABILITY; DRUG URINE LEVEL; ENTEROBACTER CLOACAE; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KLEBSIELLA PNEUMONIAE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NORMAL WEIGHT; OBESITY; OPEN STUDY; PHARMACOLOGICAL PARAMETERS; PROSPECTIVE STUDY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; URINALYSIS; VOMITING; WILD TYPE;

GLYCYLCYCLINES; MINOCYCLINE; OBESITY; PHARMACODYNAMICS; PHARMACOLOGY;

ACINETOBACTER BAUMANNII; ADMINISTRATION, INTRAVENOUS; ADULT; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, LIQUID; ENTEROBACTER CLOACAE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; OBESITY; PROSPECTIVE STUDIES; SERUM; TANDEM MASS SPECTROMETRY; URINE; YOUNG ADULT;

EID: 84890366083     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt299     Document Type: Article

References (29)

1. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008; 62 Suppl 1: i11-6.
2. Tasina E, Haidich AB, Kokkali S et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-44.
3. Yahav D, Lador A, Paul M et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-71.
4. Rubino CM, Forrest A, Bhavnani SM et al. Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Antimicrob Agents Chemother 2010; 54: 5180-6.
5. Van Wart SA, Owen JS, Ludwig EA et al. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 2006; 50: 3701-7.
6. PaiMP. Drug dosing based onweight and body surface area:mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012; 32: 856-68.
7. The NHS Information Centre, Lifestyle Statistics. Statistics on Obesity, Physical Activity and Diet: England, 2012. http://www.aso.org.uk/wp-content/uploads/downloads/2012/03/2012-Statistics-on-Obesity-Physical-Activityand- Diet-England.pdf (9 July 2013, date last accessed).
8. Ogden CL, Carroll MD, Kit BK et al. Prevalence of obesityand trends in body mass index amongUS children and adolescents, 1999-2010. JAMA2012; 307: 483-90.
9. Morales E, Praga M. The effect ofweight loss in obesityand chronic kidney disease. Curr Hypertens Rep 2012; 14: 170-6.
10. Tzouvelekis LS, Markogiannakis A, Psichogiou M et al. Carbapenemases in Klebsiellapneumoniae andother Enterobacteriaceae:anevolving crisis of global dimensions. Clin Microbiol Rev 2012; 25: 682-707.
11. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.
12. Tygacilw, Tigecycline IV. Full Prescribing Information. http://www. pfizerpro.com/hcp/tygacil/prescribing (22 Sep 2012, date last accessed).
13. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-81.
14. Hoffmann M, DeMaio W, Jordan RA et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007; 35: 1543-53.
15. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource, 2009.
16. Akaike H. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 1979; 66: 237-42.
17. Meagher AK, Passarell JA, Cirincione BB et al. Exposure-response analysis of the efficacy of tigecycline in patients with complicated skin and skin-structure infections. In: Abstracts of the Fifteenth European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, 2005. Abstract 1184. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
18. Passarell JA, Meagher AK, Liolios K et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008; 52: 204-10.
19. Bhavnani SM, Rubino CM, Ambrose PG et al. Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. Antimicrob Agents Chemother 2010; 54: 1207-12.
20. Tigecycline-EUCAST Rationale Document 2006. Rationale for the EUCAST Clinical Breakpoints. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Tigecyclinerationale1.0.pdf (29 October 2012, date last accessed).
21. MoutonJW, DudleyMN, CarsOet al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7.
22. Comets E, Brendel K, Mentré F. Computing normalized prediction distribution errors to evaluate nonlinear mixed-effects models: the NPDE add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-66.
23. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
25. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010; 17: e53-62.
26. Janmahasatian S, Duffull SB, Ash S et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
27. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 2011; 7: 697-706.
28. Korth-Bradley JM, Troy SM, Matschke K et al. Tigecycline pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol 2012; 52: 1379-87.
29. Van Wart SA, Cirincione BB, Ludwig EA et al. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol 2007; 47: 727-37.